NEUROCRINE BIOSCIENCES INC
For the period ended Jun 30, 2026. Filed Jul 31, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Jul 31, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
During the period from April 1, 2026 to June 30, 2026, our officers (as defined in Rule 16a-1(f) under the Exchange Act) and/or directors adopted orterminated contracts, instructions or written plans for the purchase or sale of our securities as noted below:
| Name and Title | Action | Date | Trading Arrangement | Total Shares Authorized to be Sold*** | Expiration Date |
|---|---|---|---|---|---|
| Rule 10b5-1* · Non-Rule 10b5-1** | |||||
| Eric Benevich | Adoption | 6/9/2026 | X | 15,300 | 5/31/2027 |
| Chief Commercial Officer | |||||
| Matthew Abernethy | Adoption | 5/22/2026 | X | 77,176 | 5/22/2027 |
| Chief Financial Officer | |||||
| George Morrow | Adoption | 5/26/2026 | X | 15,000 | 5/22/2027 |
| Director | |||||
- Intended to satisfy the affirmative defense of Rule 10b5-1(c)
** Not intended to satisfy the affirmative defense of Rule 10b5-1(c)
*** Represents the maximum number of shares that may be sold pursuant to the 10b5-1 arrangement. The number of shares sold is dependent on the satisfaction of certain conditions as set forth in the written plan and the satisfaction of applicable vesting conditions of equity awards.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.